Cardiovascular risk profile in individuals initiating treatment for overactive bladder – Challenges and learnings for comparative analysis using linked claims and electronic medical record databases

For managing overactive bladder (OAB), mirabegron, a β3 adrenergic receptor agonist, is typically used as second-line pharmacotherapy after antimuscarinics. Therefore, patients initiating treatment with mirabegron and antimuscarinics may differ, potentially impacting associated clinical outcomes. Wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Vonesh, E., Gooch, K. L., Khangulov, V., Schermer, C. R., Johnston, K. M., Szabo, S. M., Rumsfeld, J. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191128/
https://www.ncbi.nlm.nih.gov/pubmed/30325968
http://dx.doi.org/10.1371/journal.pone.0205640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191128/
https://www.ncbi.nlm.nih.gov/pubmed/30325968
http://dx.doi.org/10.1371/journal.pone.0205640

Ejemplares similares